Leaders in medicine for muscle disease
At Edgewise, we’re on a mission to discover new medicines that improve the lives of people facing serious muscle disease
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on creating novel precision medicines for the treatment of rare muscle disorders. Our intimate knowledge of integrated muscle physiology at a whole-body level allows us to develop innovative solutions for patients with muscle disease where significant unmet medical need exists. By protecting and improving muscle health, our goal is to dramatically enhance the lives of people living with progressive muscle disorders.
OUR COMMITMENT TO MUSCULAR DYSTROPHY
Learn about our unique, muscle-targeted approach to Duchenne, Becker, and Limb-Girdle muscular dystrophies, and McArdle disease.
OUR COMMITMENT TO HYPERTROPHIC CARDIOMYOPATHY (HCM)
Learn more about EDG-7500,
a first-in-class oral, selective, cardiac
sarcomere modulator.
MOVING MUSCLE HEALTH FORWARD
The path to effective therapies starts with the patient. People living with rare muscle disorders don’t let the disease define them. Our goal is to develop innovative therapies for progressive muscle disorders, with the same boldness and courage of the patients and families.
PROTECTING MUSCLES
Powered by our proprietary drug discovery platform, Edgewise Therapeutics is leading the development of a novel and holistic therapeutic approach to protect muscle.
Transforming Muscle Research
We know that for patients with rare muscle disorders, every day without an effective treatment is a day too late. We are driven by this urgency to develop novel precision medicines for severe and rare disorders.
Our Values
connection
excellence
courage
Latest News
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
April, 15 2024
View MoreEdgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
April, 15 2024
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
March, 28 2024
View MoreEdgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
March, 28 2024
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
March, 27 2024
View MoreEdgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
March, 27 2024